Breaking News Instant updates and real-time market news.

SYK

Stryker

$173.64

0.56 (0.32%)

08:12
07/10/18
07/10
08:12
07/10/18
08:12

Stryker appoints Timothy Scannell COO

Stryker is shifting responsibility for all of our operating businesses and regions under Timothy Scannell who will be appointed President and COO effective August 1. In his new role, Tim will drive growth and operating leverage across all of Stryker's businesses while promoting globalization and collaboration across our commercial units. Scannell began his career with Stryker's Endoscopy business in 1990 where he served in sales and marketing leadership roles.

  • 12

    Jul

  • 24

    Jul

SYK Stryker
$173.64

0.56 (0.32%)

06/12/18
FBCO
06/12/18
NO CHANGE
Target $151
FBCO
Outperform
Credit Suisse would be surprised to see J&J bid for Boston Scientific
Credit Suisse analyst Vamil Divan would be surprised to see Johnson & Johnson (JNJ) bid for Boston Scientific (BSX), following a report that Stryker (SYK) had approached Boston about a possible acquisition. In general, the analyst believes Johnson & Johnson prefers smaller, targeted acquisitions to larger deals and prefers to obtain technology at an earlier stage before the market has assigned proper value to it. Divan reiterates an Outperform rating and $151 price target on Johnson & Johnson shares.
06/12/18
MSCO
06/12/18
NO CHANGE
Target $186
MSCO
Overweight
Morgan Stanley says Stryker would have to pay $38-42/share for Boston Scientific
After The Wall Street Journal said Stryker (SYK) may have interest in acquiring Boston Scientific (BSX), Morgan Stanley analyst David Lewis noted that three out of five of the previous "transformative deals" in the space since 2015 - namely BD/Bard, Medtronic/Covidien, and Zimmer/Biomet - have underperformed. Boston is an attractive asset, but the strategic rationale beyond "bigger is better," which is a view to which he does not ascribe, is less clear, said Lewis. He believes Stryker will need to pay a 20-30% premium to Boston Scientific's prior trading range, suggesting a $38-$42 per share takeout price, and sees a path to 15% accretion and a 6% return on invested capital in such a scenario. Lewis has an Overweight rating and $186 price target on Stryker shares.
06/25/18
PIPR
06/25/18
NO CHANGE
Target $61
PIPR
Neutral
Stryker acquisition of SafeAir may pose thread to CONMED, says Piper Jaffray
Piper Jaffray analyst Matt O'Brien says that today's announcement of Stryker (SYK) acquiring SafeAir marks the second time that the company tried to enter the surgical smoke evacuation market, which it likely views as an "appealing" market. The analyst notes that the deal could eventually result in a product that could pose a competitive threat to CONMED (CNMD), though he also thinks that it should take Stryker some time to refine the SafeAir products and properly commercialize them. O'Brien keeps his Neutral rating and $61 price target on CONMED.
06/27/18
BERN
06/27/18
INITIATION
Target $177
BERN
Market Perform
Stryker initiated with a Market Perform at Bernstein
Bernstein analyst Lee Hambright started Stryker with a Market Perform rating and $177 price target saying that after 5 straight years of organic growth acceleration, he forecasts modest deceleration in 2018 on an aging product cycle in endoscopy, tough comps and growing base in Neuro, and continued spine market weakness.

TODAY'S FREE FLY STORIES

INXN

Interxion

$64.05

0.77 (1.22%)

07:21
07/17/18
07/17
07:21
07/17/18
07:21
Initiation
Interxion initiated  »

Interxion resumed with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Aug

07:20
07/17/18
07/17
07:20
07/17/18
07:20
General news
FX Update: The Dollar remained on a softening tack »

FX Update: The Dollar…

BAESY

BAE Systems

$0.00

(0.00%)

07:19
07/17/18
07/17
07:19
07/17/18
07:19
Periodicals
BAE Systems wants international partners for UK fighter project, Reuters says »

BAE Systems wants to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INAP

Internap

$11.31

-0.63 (-5.28%)

07:19
07/17/18
07/17
07:19
07/17/18
07:19
Initiation
Internap initiated  »

Internap resumed with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

V

Visa

$138.45

-0.91 (-0.65%)

, MA

MasterCard

$204.05

-1.86 (-0.90%)

07:19
07/17/18
07/17
07:19
07/17/18
07:19
Recommendations
Visa, MasterCard analyst commentary  »

Visa price target raised…

V

Visa

$138.45

-0.91 (-0.65%)

MA

MasterCard

$204.05

-1.86 (-0.90%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 26

    Jul

FDC

First Data

$22.24

-0.06 (-0.27%)

07:19
07/17/18
07/17
07:19
07/17/18
07:19
Recommendations
First Data analyst commentary  »

First Data price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jul

EQIX

Equinix

07:17
07/17/18
07/17
07:17
07/17/18
07:17
Initiation
Equinix initiated  »

Equinix resumed with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Aug

MA

MasterCard

$204.05

-1.86 (-0.90%)

07:17
07/17/18
07/17
07:17
07/17/18
07:17
Recommendations
MasterCard analyst commentary  »

MasterCard price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

AUTL

Autolus Therapeutics

$23.00

2.11 (10.10%)

07:16
07/17/18
07/17
07:16
07/17/18
07:16
Initiation
Autolus Therapeutics initiated  »

Autolus Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AVT

Avnet

07:15
07/17/18
07/17
07:15
07/17/18
07:15
Initiation
Avnet initiated  »

Avnet initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ARW

Arrow Electronics

$77.09

-0.47 (-0.61%)

07:15
07/17/18
07/17
07:15
07/17/18
07:15
Initiation
Arrow Electronics initiated  »

Arrow Electronics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QURE

uniQure

$35.08

-4.41 (-11.17%)

, PFE

Pfizer

$37.39

-0.14 (-0.37%)

07:15
07/17/18
07/17
07:15
07/17/18
07:15
Recommendations
uniQure, Pfizer analyst commentary  »

uniQure pullback on…

QURE

uniQure

$35.08

-4.41 (-11.17%)

PFE

Pfizer

$37.39

-0.14 (-0.37%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

  • 10

    Sep

AMBA

Ambarella

$37.58

-0.32 (-0.84%)

07:14
07/17/18
07/17
07:14
07/17/18
07:14
Initiation
Ambarella initiated  »

Ambarella initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BF.B

Brown-Forman, also tag with BFA, BFB

$51.18

0.14 (0.27%)

, BFA

Brown-Forman, also tag with BF.A, BF.B

$0.00

(0.00%)

07:13
07/17/18
07/17
07:13
07/17/18
07:13
Upgrade
Brown-Forman, also tag with BFA, BFB, Brown-Forman, also tag with BF.A, BF.B, Brown-Forman, also tag with BF.A, BF.B rating change  »

Brown-Forman upgraded to…

BF.B

Brown-Forman, also tag with BFA, BFB

$51.18

0.14 (0.27%)

BFA

Brown-Forman, also tag with BF.A, BF.B

$0.00

(0.00%)

BFB

Brown-Forman, also tag with BF.A, BF.B

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$207.33

(0.00%)

07:13
07/17/18
07/17
07:13
07/17/18
07:13
Periodicals
Facebook uses 'shielded review' process for popular pages, The Guardian reports »

Leading far-right…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

  • 25

    Jul

  • 18

    Sep

CHUY

Chuy's

07:11
07/17/18
07/17
07:11
07/17/18
07:11
Downgrade
Chuy's rating change  »

Chuy's downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Aug

DLR

Digital Realty

$115.64

-0.66 (-0.57%)

07:11
07/17/18
07/17
07:11
07/17/18
07:11
Initiation
Digital Realty initiated  »

Digital Realty resumed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

NFLX

Netflix

$400.24

4.32 (1.09%)

07:10
07/17/18
07/17
07:10
07/17/18
07:10
Recommendations
Netflix analyst commentary  »

Netflix valuation remains…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BLMN

Bloomin' Brands

$20.72

-0.36 (-1.71%)

07:09
07/17/18
07/17
07:09
07/17/18
07:09
Upgrade
Bloomin' Brands rating change  »

Bloomin' Brands…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jul

CANF

Can-Fite BioPharma

$1.23

-0.04 (-3.15%)

07:09
07/17/18
07/17
07:09
07/17/18
07:09
Hot Stocks
Can-Fite BioPharma receives patent from China, Australia for sexual dysfunction »

Can-Fite BioPharma…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

COR

CoreSite Realty

$112.91

-0.86 (-0.76%)

07:09
07/17/18
07/17
07:09
07/17/18
07:09
Initiation
CoreSite Realty initiated  »

CoreSite Realty resumed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

INNT

Innovate Biopharmaceuticals

$8.07

-15.65 (-65.98%)

07:08
07/17/18
07/17
07:08
07/17/18
07:08
Initiation
Innovate Biopharmaceuticals initiated  »

Innovate…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

AST

Asterias

$1.70

-0.05 (-2.86%)

07:08
07/17/18
07/17
07:08
07/17/18
07:08
Hot Stocks
Asterias provides six month data readout for AST-OPC1 Phase 1/2a clinical trial »

Asterias Biotherapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NSU

Nevsun Resources

$3.21

-0.06 (-1.84%)

07:07
07/17/18
07/17
07:07
07/17/18
07:07
Hot Stocks
Nevsun Resources advises that no formal offer has yet been made by Lundin Mining »

Nevsun Resources…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

CONE

CyrusOne

$61.71

0.08 (0.13%)

07:06
07/17/18
07/17
07:06
07/17/18
07:06
Initiation
CyrusOne initiated  »

CyrusOne resumed with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Aug

  • 09

    Aug

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.